Our top pick for
Vaxart, Inc is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxart employs 16 staff and has a trailing 12-month revenue of around USD$7.8 million.
|52-week range||USD$0.266 - USD$17.49|
|50-day moving average||USD$7.5557|
|200-day moving average||USD$5.3783|
|Wall St. target price||USD$19.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.033|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-27)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-27)||-100.00%|
|1 year (2019-09-27)||-100.00%|
|2 years (2018-09-27)||-100.00%|
|3 years (2017-09-27)||-100.00%|
|5 years (2015-09-25)||-100.00%|
|Revenue TTM||USD$7.8 million|
|Gross profit TTM||USD$-4,678,000|
|Return on assets TTM||-17.91%|
|Return on equity TTM||-78.26%|
|Market capitalisation||USD$752.4 million|
TTM: trailing 12 months
There are currently 13.4 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 2.9% down from 13.8 million last month.
There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.
Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 14.4 million). Vaxart's SIR currently stands at 0.93. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 930 shares are currently held short.
However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 120 shares are currently held short) or 0.1613% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 161 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.
Find out more about how you can short Vaxart stock.
We're not expecting Vaxart to pay a dividend over the next 12 months.
Vaxart's shares were split on a 1:11 basis on 14 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.
Over the last 12 months, Vaxart's shares have ranged in value from as little as $0.266 up to $17.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is -0.0427. This would suggest that Vaxart's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vaxart has bucked the trend.
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.